NCT07042633 Mechanism of Gamma Oscillation Synchronization in the Prefrontal-hippocampal Circuit for Memory Dysfunction in Patients With White Matter Lesions of Cerebral Small Vessel Disease
| NCT ID | NCT07042633 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Vascular Cognitive Impairment |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-07 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-03-07 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease is still unclear. The disrupted synchronization of gamma oscillations in the prefrontal-hippocampal circuit is a potential key mechanism. Our study has demonstrated that white matter lesions lead to demyelination of the connection tracts between the prefrontal lobe and hippocampus, which is closely related to memory dysfunction. However, further studies are required to explore if these microstructural changes in white matter tracts influence memory function by affecting gamma oscillations. Thus, this project will use the previously established episodic memory task and event-related potential to determine the changes in gamma oscillations in the prefrontal-hippocampal circuit and the effects on memory encoding and retrieval. Combining multimodal imaging, we will explore the mediating role of white matter microstructure damage, and establish a machine learning prediction model for memory impairment. In addition, transcranial alternation current stimulation (tACS) will be used to investigate the mechanisms of memory improvement by regulating the prefrontal-hippocampal gamma oscillations. This project will clarify the neural oscillation mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease, with the expectation of providing new predictive indicators and interventions.
Eligibility Criteria
Inclusion Criteria: * \- Individuals with cerebral small vessel disease, normal cognition or mild cognitive impairment subjects; * Participants with complete demographic data, neuropsychiatric scale assessments, imaging data, and EEG data. Exclusion Criteria: * Severe aphasia, physical disability, or other conditions preventing completion of neuropsychological assessments; * History of cerebrovascular stroke with documented neurological deficits during onset and corresponding lesions on neuroimaging; * Neurological disorders that may cause cognitive impairment, including alcohol abuse, drug addiction, traumatic brain injury, epilepsy, encephalitis, or normal-pressure hydrocephalus; * Systemic diseases potentially contributing to mild cognitive impairment (e.g., hepatic/renal insufficiency, endocrine disorders, vitamin deficiencies); * Current diagnosis of major depressive disorder or psychiatric disorders.
Frequently Asked Questions
Who can join the NCT07042633 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 75 Years, studying Vascular Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07042633 currently recruiting?
Yes, NCT07042633 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xuanwu Hospital, Beijing to inquire about joining.
Where is the NCT07042633 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07042633 clinical trial?
NCT07042633 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 150 participants.